New directive brings manufacturers, pharmacies, gyms, distributors, e-comm platforms under stricter regulatory scrutiny; action promised against misleading health claims, unapproved ingredients and illegal sales
The Maharashtra Food and Drug Administration (FDA) has issued a comprehensive state wide compliance order tightening regulations governing health supplements, nutraceuticals, sports nutrition products and foods for special dietary and medical purposes. The order, issued by Commissioner of Food Safety, Tukaram Mundhe takes immediate effect and covers the entire supply chain, from manufacturers and importers to pharmacies, gyms, retailers and online marketplaces.
The regulatory move comes amid growing concerns over misleading health claims, the use of non-permitted ingredients, undeclared drug substances and the sale of products without valid food safety licences. In a coordinated state-wide enforcement drive conducted on November 13, the FDA inspected 17 establishments across six divisions and seized stock valued at Rs1,38,95,852. Samples of the seized products have been sent for laboratory analysis, with further legal action to follow based on the findings.
Pharmacies, gyms and online sellers brought under regulatory scanner
Under the new order, every business involved in the manufacture, storage, distribution or sale of health supplements and nutraceuticals must comply with the Food Safety and Standards Act, 2006, and applicable FSSAI regulations.
The directive specifically clarifies that pharmacies, medical stores, gymnasiums, fitness centres and wellness establishments must obtain a valid FSSAI food licence or registration to sell such products, even if they already hold licences under other laws.
The order also applies to contract manufacturers, brand owners, marketers, importers, wholesalers, warehouses, distributors, hospital suppliers and e-commerce platforms.
Maharashtra currently has 1,100 operative food business licences under the health supplement and nutraceutical categories, including 313 manufacturers, 759 relabellers and 28 repackers. All these businesses will now come under risk-based regulatory inspections.
Strict action against misleading health and disease-cure claims
The FDA has prohibited health supplement manufacturers and marketers from making claims that their products can treat, cure, mitigate or prevent diseases.
Representations such as 'recommended by doctors or nutritionists', photographs of physicians and claims suggesting that products are clinically prescribed will also face regulatory action.
The restrictions extend beyond product packaging to television advertisements, websites, mobile applications, e-commerce listings, social media promotions and paid influencer campaigns. Businesses are required to preserve their advertising material for three years.
The FDA has also prohibited the use of the term 'ORS' in product names, brand names and trademarks.
Unapproved ingredients and undeclared steroids under special scrutiny
The department has identified the use of unapproved ingredients and suspected undeclared pharmaceutical substances as major areas of concern.
During the November 13 enforcement drive, authorities detected the use of Magnesium Acetyl Taurate and Nicotinamide Mononucleotide (NMN), ingredients whose product approval applications had been rejected by FSSAI.
Stock worth Rs.1.38 crore was seized across the state. The samples have been sent for laboratory examination on suspicion of being substandard, unsafe and misbranded.
The FDA will intensify surveillance of sports nutrition, weight-loss, sexual-wellness, herbal and imported products, particularly those suspected of containing undeclared steroids, hormones or other drug substances.
Products suspected of having drug-like characteristics will also be referred to the Drugs Department or the relevant AYUSH licensing authority, as applicable.
Detailed labelling and ingredient disclosure made mandatory
The new compliance order places particular emphasis on transparent product labelling and consumer safety.
Manufacturers must clearly mention the specific food category on product packaging, such as 'HEALTH SUPPLEMENT', 'NUTRACEUTICAL', 'FOOD FOR SPECIAL DIETARY USE' or 'PROBIOTIC FOOD'.
The statement 'NOT FOR MEDICINAL USE' must appear prominently on health supplements, nutraceuticals and prebiotic and probiotic products.
For botanical ingredients, manufacturers must disclose the specific plant part used and include all prescribed warnings and cautionary statements. In the case of Ashwagandha, only roots and root extracts are permitted under the cited FDA advisory.
Other requirements include recommended daily dosage, potential side effects, contraindications, nutritional information, and percentage of recommended dietary allowance (RDA), batch details, expiry dates, allergen declarations and appropriate storage instructions.
The order also restricts vitamins and minerals to prescribed limits, including the applicable limit of one RDA for Indians.
Products intended for special medical purposes must carry the declaration 'RECOMMENDED TO BE USED UNDER MEDICAL ADVICE ONLY' on the front of the pack.
Rs.1.39 crore stock seized across six divisions
The state-wide search operation conducted on November 13 covered 17 establishments across Pune, Nashik, Konkan (Thane), Nagpur, Amravati and Chhatrapati Sambhajinagar divisions.
The seized products have been kept in safe custody pending laboratory reports. Depending on the findings of the Food Analyst, the department will initiate adjudication proceedings or prosecution before the competent court.
Heavy penalties and imprisonment for violations
The FDA has warned that businesses found violating the regulations could face improvement notices, suspension or cancellation of licences, product seizures, mandatory recalls, financial penalties and criminal prosecution.
Under the Food Safety and Standards Act, penalties for misleading advertisements can extend to Rs10 lakh, while carrying on a food business without a valid licence can attract a penalty of up to Rs10 lakh.
In cases involving unsafe food, including products containing undeclared drugs or prohibited substances, imprisonment may extend to three months for violations not resulting in injury, one year for non-grievous injury and six years for grievous injury.
Where consumption results in death, the punishment can extend from a minimum of seven years' imprisonment to life imprisonment, along with a fine of at least Rs10 lakh.
The FDA has directed its Joint Commissioners and Designated Officers across Maharashtra to prepare lists of businesses operating in their jurisdictions and undertake further risk-based inspections. Online surveillance and test purchases will also form part of the enforcement strategy.
FDA appeals to consumers to remain vigilant
The department has urged consumers to purchase health supplements only from licensed outlets and trusted online sellers, insist on bills and carefully verify FSSAI licence numbers, ingredients, dosage instructions, batch numbers, expiry dates and mandatory warnings.
Consumers have also been advised to avoid products promising rapid weight loss, instant muscle gain or cures for diabetes, blood pressure and other diseases.
Children, pregnant and lactating women, senior citizens and individuals undergoing medical treatment should consume such products only after consulting a qualified medical professional.
Consumers can report suspicious products, misleading advertisements or quality-related complaints through the FDA's toll-free helpline 1800-222-365 or its online grievance portal at
https://complaints.mahafda.in. The department has assured that the identity of complainants will be kept confidential.
Emphasising the department's commitment to public health, Commissioner Tukaram Mundhe said that products marketed in the name of health must not be allowed to compromise citizens' well-being and warned that no violator, whether a manufacturer, brand owner or online seller, would be spared.
The state-wide compliance order is a significant step towards strengthening oversight of Maharashtra's rapidly expanding health supplement and nutraceutical market, with a clear focus on consumer protection, product transparency and accountability across the supply chain.